Document Detail

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
MedLine Citation:
PMID:  22447805     Owner:  NLM     Status:  Publisher    
AimsThe efficacy of durable polymer drug-eluting stents (DES) is delivered at the expense of delayed healing of the stented vessel. Biodegradable polymer DES aim to avoid this shortcoming and may potentially improve long-term clinical outcomes, with benefit expected to accrue over time. We sought to compare long-term outcomes in patients treated with biodegradable polymer DES vs. durable polymer sirolimus-eluting stents (SES).Methods and resultsWe pooled individual patient data from three large-scale multicentre randomized clinical trials (ISAR-TEST 3, ISAR-TEST 4, and LEADERS) comparing biodegradable polymer DES with durable polymer SES and assessed clinical outcomes during follow-up through 4 years. The efficacy endpoint of interest was target lesion revascularization and the safety endpoint of interest was definite stent thrombosis. Out of 4062 patients included in the present analysis, 2358 were randomly assigned to treatment with biodegradable polymer DES (sirolimus-eluting, n= 1501; biolimus-eluting, n= 857) and 1704 patients to durable polymer SES. No heterogeneity across the trials was observed in analyses of the primary and secondary endpoints. At 4 years, the risk of target lesion revascularization was significantly lower among patients treated with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.82, 95% CI 0.68-0.98, P= 0.029). In addition, the risk of stent thrombosis was significantly reduced with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.56, 95% CI 0.35-0.90, P= 0.015), driven by a lower risk of very late stent thrombosis (hazard ratio 0.22, 95% CI 0.08-0.61, P= 0.004). In keeping with this, in landmark analysis between 1 and 4 years, the incidence of myocardial infarction was lower for patients treated with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.59, 95% CI 0.73-0.95, P= 0.031).ConclusionBiodegradable polymer DES improve safety and efficacy compared with durable polymer SES during long-term follow-up to 4 years.
Giulio G Stefanini; Robert A Byrne; Patrick W Serruys; Antoinette de Waha; Bernhard Meier; Steffen Massberg; Peter Jüni; Albert Schömig; Stephan Windecker; Adnan Kastrati
Related Documents :
17315055 - Treatment persistence and compliance with medications for chronic obstructive pulmonary...
8894745 - Intravenous immunoglobulin therapy for refractory myositis.
1601015 - Immunosuppressive treatment for juvenile myasthenia gravis.
9074565 - Guillain-barré syndrome. a severe case calling for intensive treatment.
20585195 - Correlation between estimated glomerular filtration rate (egfr) and apparent diffusion ...
23419385 - Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites:...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-24
Journal Detail:
Title:  European heart journal     Volume:  -     ISSN:  1522-9645     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Cardiology, Bern University Hospital, Bern, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Disruption of the X-loop turn of the prion protein linked to scrapie resistance.
Next Document:  Clinical Context and Mechanism of Functional Tricuspid Regurgitation in Patients with and without Pu...